LIB003
Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430)
Study title/design Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430) Trial NCT04798430/LIB003-007 (Enrolling by invitation). Estimated primary completion: October 30 2024. Estimated study completion: December 31 2024. Aim To…
read more »
Trial to evaluate efficacy and safety of lerodalcibep (LIB003) and inclisiran in high risk CVD patients (LIBerate-VI) (NCT05004675)
Study title/design Trial to evaluate efficacy and safety of lerodalcibep (LIB003) and inclisiran in high risk CVD patients (LIBerate-VI) (NCT05004675) Trial NCT05004675/LIB003-012 (Active, not recruiting). Estimated primary completion: 30 May 2024. Estimated study completion: 30 July 2024. Aim To compare LDL-C reductions with lerodalcibep 300…
read more »
Study of efficacy and safety of lerodalcibep (LIB003) in patients with CVD on statins requiring additional LDL-C reduction (LIBerate-CVD) (NCT04797247)
Study title/design Study of efficacy and safety of lerodalcibep (LIB003) in patients with CVD on statins requiring additional LDL-C reduction (LIBerate-CVD) (NCT04797247) Trial NCT04797247/LIB003-005 (Completed) Aim To assess LDL-C reductions at week 52 with monthly (Q4W) dosing of lerodalcibep 300 mg s.c. compared to placebo…
read more »
Study to assess the efficacy and safety of lerodalcibep (LIB003) in patients with HeFH on oral lipid therapy needing further LDL-C reduction (LIBerate-FH) (NCT04797104)
Study title/design Study to assess the efficacy and safety of lerodalcibep (LIB003) in patients with HeFH on oral lipid therapy needing further LDL-C reduction (LIBerate-FH) (NCT04797104) Trial NCT04797104/LIB003-004 (Completed) Aim To assess LDL-C reductions at week 24 and the mean of weeks 22 and 24…
read more »
Study of long term efficacy and safety of lerodalcibep (LIB003) in patients with CVD or high risk for CVD needing further LDL-C Reduction (LIBerate-HR, NCT04806893)
Study title/design Study of long term efficacy and safety of lerodalcibep (LIB003) in patients with CVD or at high risk of CVD needing further LDL-C reduction (LIBerate-HR, NCT04806893) Trial NCT04806893/LIB003-006 (Completed) Aim To assess LDL-C reductions at week 52 with lerodalcibep 300 mg s.c. every…
read more »
Phase 3 study to evaluate the efficacy and safety of lerodalcibep (LIB003) with evolocumab in HoFH (NCT04034485)
Study title/design Phase 3 study to evaluate the efficacy and safety of lerodalcibep (LIB003) with evolocumab in HoFH (NCT04034485) Trial CT04034485/LIB003-003 (Completed) Aim To compare the safety, tolerability and LDL-C response after 24 weeks of LIB003 300 mg s.c every 4 weeks with evolocumab 420…
read more »
Trial to evaluate efficacy and safety of lerodalcibep (LIB003), evolocumab and alirocumab in patients at high risk CVD (LIBerate-H2H) (NCT04790513)
Study title/design Trial to evaluate efficacy and safety of lerodalcibep (LIB003), evolocumab and alirocumab in patients at high risk CVD (LIBerate-H2H) (NCT04790513) Trial NCT04790513/LIB003-011 (Completed). Aim To compare LDL-C reductions at week 12 of monthly lerodalcibep 300 mg s.c., evolocumab 420 mg s.c., and alirocumab…
read more »
Open label extension to evaluate the longer term efficacy of lerodalcibep (LIB003) (NCT03847974)
Study title/design Open label extension to evaluate the longer term efficacy of lerodalcibep (LIB003) (NCT03847974) Trial NCT03847974 (Completed) Aim To assess the longer term safety, tolerability and LDL-C lowering efficacy of LIB003 administered every 4 weeks, after 52 weeks. Study Design Open label Phase 2b…
read more »
Study to evaluate efficacy and safety of LIB003 in patients on lipid-lowering therapy needing additional LDL-C reduction (NCT03549260)
Study title/design Study to evaluate efficacy and safety of LIB003 in patients on lipid-lowering therapy needing additional LDL-C reduction (NCT03549260) Trial NCT03549260/LIB003-002 (Completed) Aim To assess the LDL-C lowering efficacy of different doses of LIB003 administered every 4 weeks in participants on stable statin and/or…
read more »
